(RTTNews) - Viking Therapeutics, Inc. (VKTX), Wednesday announced positive data from Phase 1b study of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). X-ALD is a rare and often fatal ...
On Wednesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released data from the Phase 1b trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRβ), in patients with ...
Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic disorder X-linked adrenoleukodystrophy, or X-ALD. San ...
Viking Therapeutics Inc.’s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...
This rare and devastating genetic disease can now be effectively treated with haploidentical stem cell transplantation.
NeuroVia Closes Series A Financing Round of $14M to Develop Novel Treatment Option for X-ALD Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NeuroVia, Inc., a biopharmaceutical company focused on developing innovative therapies for rare genetic neurological diseases, announced the closing of a Series A ...
Notes: 1) Least squares mean change from baseline to Day 28. 2) Two-sided t-test using mixed model for repeated measures. 3) C26:0-LPC data for 20 mg, 40 mg cohorts include results from n=7, n=8 ...
There are plans to add two more genetic disorders for screening for Wisconsin’s newborn screening program. X-Linked Adrenoleukodystrophy (X-ALD) and Mucopolysaccharidosis Type 1 (MPS 1) will be part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results